Alpha-1 Antitrypsin Deficiency and Alpha1-Proteinase Inhibitor Therapy
Research activity in Alpha-1 antitrypsin deficiency centers on alpha1-proteinase inhibitor replacement, including subcutaneous and intravenous administration in people with AATD.
- Alpha1-Proteinase Inhibitor replacement
- Subcutaneous and intravenous delivery
- Pharmacokinetics and systemic exposure
- Long-term safety in AATD
The sponsor also studies treatment effects in pulmonary emphysema linked to alpha-1-antitrypsin deficiency, with attention to preserving lung structure and limiting disease progression.
Pulmonary Emphysema and Lung Preservation
Within pulmonary emphysema due to alpha-1-antitrypsin deficiency, the clinical focus includes therapies intended to slow lung tissue loss and support respiratory stability.
- Emphysema associated with AATD
- Lung density and structural preservation
- Intravenous augmentation therapy
These studies reflect sustained interest in respiratory disease management for patients with inherited protease inhibitor deficiency.
Hypogammaglobulinemia and Infection Prevention
Another research area is hypogammaglobulinemia in patients with hematologic malignancies, where the sponsor evaluates immune support aimed at reducing major bacterial infections.
- B-cell chronic lymphocytic leukemia
- Multiple myeloma
- Non-Hodgkin lymphoma
- Recurrent or severe infections
This work addresses infection risk in people whose immune function is compromised by B-cell malignancies and related antibody deficiency.
